Board of Directors
Allen Lichter, MD - Chair
Allen S. Lichter, MD, earned his bachelor’s degree (1968) and medical degree (1972) from the University of Michigan. He trained in radiation oncology at University of California, San Francisco, before joining the faculty at Johns Hopkins University, and later the National Cancer Institute.
From 1984- 2006, Dr. Lichter was at the University of Michigan in two significant leadership roles. He served as Professor and Chair of Radiation Oncology from 1984-1998 and as Dean of the Medical School from 1998 - 2006. Prior to his tenure at the University of Michigan, Dr. Lichter was the Director of the Radiation Therapy Section of the NCI’s Radiation Oncology Branch. Dr. Lichter’s research and development of three-dimensional treatment planning and dose delivery led to a Gold Medals from the American Society for Therapeutic Radiology and Oncology (ASTRO) and from the Radiologic Society of North America (RSNA). In 2002 he was elected to membership in the Institute of Medicine of the National Academies of Science (now the National Academy of Medicine).
From 2006-2016 Dr. Lichter served as Chief Executive Officer (CEO) of the American Society of Clinical Oncology (ASCO), the world's leading professional organization representing nearly 40,000 physicians and health professionals in oncology.
Dr. Lichter has held many prominent roles in the Society, including President (1998-1999), Founding Chair of ASCO’s Conquer Cancer Foundation Board, and founding Chair of the Board of Governors of CancerLinQ, ASCO’s learning health platform in oncology. He remains a member of the CancerLinQ Board.
Lawrence Baker, DO - Vice-Chair
Throughout his career as an academic clinician, Dr. Baker's overarching goal has been to improve upon the care of cancer patients. He has balanced efforts in patient care, teaching, and translational and clinical research with medical administration. The clinical research has focused upon discovery and development of new systemic therapies, clinical trial design, and late transitional research in sarcoma. Using an interdisciplinary model, his team participated in research that led to significant advances in bone sarcomas and select soft tissue sarcomas as well as for patients with anal canal cancers, head and neck cancer, and breast cancer. Dr. Baker established SARC as the consortium of worldwide experts in pediatric and medical oncology dedicated to clinical trials research in the treatment of sarcomas. In addition, he has served as PI of a sarcoma SPORE grant and the SWOG Translational Medical Science Center. Currently, Dr. Baker serves as leader of the Translational and Clinical Research Program at the University of Michigan. He established the first Sarcoma Survivorship Program emphasizing the two major adverse outcomes: recurrent cancer and acquired heart disease. The four areas of his career contributions to science include: sarcoma therapeutics, sarcoma biology, clinical trial methodology, and prevention/survivorship.
Mark J. Ratain, MD - Treasurer
Dr. Ratain is a graduate of Harvard College (A.B., 1976) and Yale University School of Medicine (M.D., 1980). His postgraduate training was completed at Johns Hopkins Hospital (Internal Medicine, 1980-3) and the University of Chicago Hospitals (Hematology/Oncology, 1983-6). He has been a faculty member in the Department of Medicine at The University of Chicago since 1986, and is currently the Leon O. Jacobson Professor of Medicine, the Director of the Center for Personalized Therapeutics and Chief Hospital Pharmacologist. In addition, he serves as the Associate Director for Clinical Sciences in the University’s Comprehensive Cancer Center, and leads the University of Chicago’s phase I oncology trials program. Dr. Ratain’s research focuses on the development of new oncology drugs and diagnostics, and he is an international leader in phase I clinical trials, pharmacogenomics, and clinical trial methodology, with over 280 original publications. He served as the first chair of the Steering Committee of the National Institutes of Health Pharmacogenetics Research Network, as well as one of the first co-chairs of the National Cancer Institute Investigational Drug Steering Committee. He currently serves as co-Editor of Pharmacogenetics and Genomics, and is a past Associate Editor of the Journal of Clinical Oncology. He is the recipient of multiple awards, including the Research Achievement Award in Clinical Pharmacology and Translational Research from the American Association of Pharmaceutical Scientists, the Rawls-Palmer Progress in Medicine Award from the American Society for Clinical Pharmacology and Therapeutics, the Translational Research Professorship from the American Society of Clinical Oncology, a Honorary Fellowship from the American College of Clinical Pharmacology, and the Award in Clinical Excellence from the Pharmaceutical Research and Manufacturers Association Foundation.
Leonard Saltz, MD - Secretary
Much of Dr. Saltz's career has been dedicated to developing new drug therapies and treatment strategies for colorectal cancer, and he has tapped the vast resources of Memorial Sloan Kettering — from various clinical departments to the Human Oncology and Pathogenesis Program, the Sloan Kettering Institute, and The Rockefeller University — to create an integrated translational research program. As Chief of the Gastrointestinal Medical Oncology Service, he looks forward to expanding this program even more in the years to come.
In addition to his role as Service Chief, he is Chair of the hospital’s Pharmacy and Therapeutics Committee and co-leader of the Colorectal Disease Management Team. He is also a Professor of Medicine at Weill Cornell Medical College. Nationally, I serve on the National Cancer Institute (NCI) Rectal and Anal Cancer Task Force and am co-leader of the Alliance NCI Cooperative Research Group efforts in colon and rectal cancers. Dr. Saltz serves on three National Comprehensive Cancer Network (NCCN) guidelines committees: colorectal cancers, neuroendocrine cancers, and unknown primary cancers.
Since 1990 he has authored or co-authored more than 150 peer-reviewed journal articles on the development of new treatments for colorectal and other gastrointestinal cancers. Dr. Saltz has also written numerous books, book chapters, monographs, and reviews on current and future treatment strategies for these diseases.
Jonas de Souza, MD, MBA - Member-at Large
Dr. de Souza is a medical oncologist at the University of Chicago. Originally from Brazil, he is a graduate of the Universidade do Estado to Rio de Janeiro, subsequently attending the University of Texas Houston for his internal medicine residency. Dr. de Souza then pursued a medical oncology fellowship at The University of Chicago, where he became a faculty in 2011 and is currently an Assistant Professor of Medicine. Dr. de Souza also holds a Master in Business Administration (MBA) from the University of Chicago Booth School of Business and has devoted his research to the study of value in cancer care, particularly on the financial toxicity cancer patients face in order to be treated. Dr. de Souza has been an early advocate for and writer about value-based reimbursement models and personalized value in oncology. He developed the only validated patient-reported outcome to assess financial toxicity in cancer patients and was the creator of the www.costofcancercare.org portal. He has several peer-reviewed articles and his work has been widely mentioned in the media.
Michael Stebbins, PhD - Member-at Large
Michael is the Laura and John Arnold Foundation's Vice President of Science and Technology. In this role, he responsible for identifying and pursuing opportunities for philanthropic investment in science and technology. He joined the foundation after serving as the assistant director for biotechnology at the White House Office of Science and Technology Policy for six years. At the White House, Michael was responsible for developing and driving initiatives in life sciences research, including the Administration’s efforts focused on improving veterans’ mental health, combating antibiotic resistance, increasing access to federally funded scientific research results, restoring pollinator health, and reforming the regulatory system for biotechnology products.
Michael previously served as a science advisor to the Obama Campaign and on the Obama Presidential Transition Team. He is the former director of biology policy for the Federation of American Scientists and the former president of Scientists and Engineers for America Action Fund. He also co-founded and served on the board of directors for Scientists and Engineers for America, and is a former adjunct professor of bioethics at the University of Pennsylvania. In addition, Michael worked as a legislative fellow for U.S. Senator Harry Reid and a public policy fellow for the National Human Genome Research Institute. Before coming to Washington, he was a senior editor at Nature Genetics. He received his B.S. in biology at SUNY Stony Brook and his Ph.D. in genetics while working at Cold Spring Harbor Laboratory.